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Hypertension is a major risk factor for cardiovascular disease and results from a complex interplay between genetic and 
environmental factors.1 Intake of caffeinated beverages might be 
associated with lower cardiovascular mortality.2 Caffeine, >70% 
of which is provided by coffee consumption,3 is metabolized by 
the liver CYP1A2 enzyme into paraxanthine (≈80%), theobro-
mine (≈12%), and theophylline (≈4%). Caffeine and caffeine 
metabolites are methylxanthines: a family of nonspecific adenos-
ine receptor antagonist with several properties, including diuretic 
and natriuretic properties.4,5 The urinary excretion of caffeine and 
caffeine metabolites is a valid measure of caffeine intake.6
The relation of blood pressure (BP) with caffeine and caffeine 
metabolites is of major interest, given their widespread consump-
tion in foods and beverages (eg, coffee, tea, cola drinks, chocolate 
products) and the public health burden of high BP. Studies on the 
effect of acute consumption of caffeine at dietary levels on BP 
produced inconsistent results,7 with a recent study restricted to 
nonsmokers showing a decrease in systolic BP (SBP).8 In a cross-
sectional study, high reported caffeine intake was associated with 
a lower prevalence of hypertension only in nonsmokers.9
To date, studies on the association of caffeine and BP have 
been limited by the use of reported caffeine intake instead of 
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measured caffeine and caffeine metabolites and the use of 
office BP instead of ambulatory BP measurement (ABPM).10 
Recognizing this, we aimed to analyze the associations 
between ambulatory BP with urinary caffeine and caffeine 
metabolites excretions in the general adult population with 
the hypothesis that caffeine and metabolites excretions are 
inversely associated with BP.
Methods
SKIPOGH (Swiss Kidney Project on Genes in Hypertension) is a 
family and population-based cross-sectional study that examines the 
genetic determinants of BP. SKIPOGH is nested within the larger 
family-based international EPOGH study (European Project on Genes 
in Hypertension). SKIPOGH uses the same methods as that imple-
mented and validated in the EPOGH study.11 SKIPOGH has been 
described elsewhere.12,13 Briefly, SKIPOGH is a multicenter study 
with participants being recruited in the cantons of Bern and Geneva 
and the city of Lausanne. Recruitment began in December 2009 and 
ended in April 2012 in Lausanne, in October 2012 in Geneva, and 
in April 2013 in Bern. Index cases were randomly selected from the 
population-based CoLaus study14 in Lausanne and from the popula-
tion-based Bus Santé study in Geneva.15 In Bern, index participants 
were randomly selected using the cantonal phone directory. The 
SKIPOGH study was approved by the institutional ethical commit-
tees of the 3 participating university hospitals. All study participants 
provided written informed consent. The study population included 
1128 participants coming from 273 nuclear families.
Participants filled in a detailed health questionnaire at home and 
attended the respective study centers in the morning where blood 
samples were collected after an overnight fast. Participants were also 
asked to collect a 24-hour urine sample, with separate day and night 
collections, for the measurement of urinary volume and electrolytes. 
Urinary sodium and potassium were measured using a Modular ana-
lyzer (Roche Diagnostics, Basel, Switzerland) in Lausanne and in 
Bern, and using the UniCel DxC 800 (Beckman Coulter, California, 
United States) in Geneva. Inter-center comparison based on 60 par-
ticipants showed high Lin’s correlation (0.99–1.00 for urinary so-
dium and 0.93–0.99 for urinary potassium). The CKD-EPI formula 
was used to calculate the estimated glomerular filtration rate.16 Body 
weight and height were measured using precision electronic scales 
(Seca™, Hamburg, Germany). Body mass index was calculated as 
weight (kilogram) divided by height squared (meter). Diabetes mel-
litus was defined as a fasting glucose ≥7 mmol/L or presence of an-
tidiabetic drug treatment (insulin or oral drugs). Participants were 
defined as smokers if currently smoking, non smokers otherwise.
Ambulatory Blood Pressure
Twenty-four hour ABPM was measured using validated Diasys Integra 
devices (Novacor, Rueil-Malmaison, France), which have fulfilled 
validation criteria of the British Hypertension Society and Association 
for the Advancement of Medical Instrumentation (AAMI) protocols.17 
Measurements were taken every 15 minutes during the day and every 
30 minutes during the night (from 10 pm to 7 am). Invalid BP values 
were defined as SBP >280 mm Hg or <60 mm Hg, diastolic BP (DBP) 
>200 mm Hg or <40 mm Hg, heart rate >200 bpm or <40 bpm, or DBP 
≥SBP.18 We used the awake and asleep periods as reported by partici-
pants to define day and night. Mean BP readings were then calculated 
using the valid 24-hour, daytime, and night-time measurements. The 
mean (min–max) number of 24-hour, daytime, and night-time mea-
surements were 68.5 (18–100), 50.6 (3–82), and 17.9 (2–33).
Urinary Caffeine and Caffeine Metabolites
Quantification of caffeine, paraxanthine, theobromine, and theophyl-
line in urine samples was performed by ultrahigh performance liquid 
chromatography (Waters ACQUITY UPLC I-Class) coupled to tan-
dem mass spectrometry with electrospray ionization (Waters Xevo 
TQ-S). Sample preparation was performed by simple dilution. Limit 
of quantification was 10 ng/mL for caffeine, paraxanthine, and the-
ophylline and 20 ng/mL for theobromine. The methods were fully 
validated according to the latest international guidelines using a 
stable isotope-labeled internal standard for each analyte. Expanded 
uncertainty (95% confidence level) calculated during routine use of 
the method was 8.2% for caffeine, 7.6% for paraxanthine, 7.8% for 
theobromine, and 8.1% for theophylline, respectively (Ansermot et 
al, manuscript in preparation, detailed method available on request).
Statistical Analysis
Continuous variables were described with mean or median and SD, SE, 
or interquartile range. Categorical variables were described with per-
centages. Twenty-four hours caffeine and paraxanthine urinary excre-
tions were categorized into quartiles and associations with ABPM tested 
and illustrated. To satisfy normality assumptions, caffeine and caffeine 
metabolites were log-transformed. Association sizes were expressed as 
a 2-fold increase in the explanatory variables (without back transforma-
tion). Log base 2 was used so that the transformed beta coefficients can 
be interpreted as the effect on BP when the excretion of caffeine, respec-
tively, caffeine metabolites, is doubled. We used mixed linear models to 
explore the associations of caffeine and caffeine metabolites levels with 
ambulatory SBP and DBP, although adjusting for major confounders, 
including sodium and potassium blood concentrations and 24-hour uri-
nary excretions, and familial correlations. We used an independent cova-
riance structure to accommodate familial dependencies. The estimations 
of the standard errors for the fixed effect parameters were model-based. 
Variables included in models as potential confounders were a priori 
considered, given their reported or potential influence on BP, methylx-
anthines, or both. The following variables were included in the models 
as potential confounders: age, sex, body mass index, oral contracep-
tive use, diabetes mellitus, current alcohol use and smoking, CKD-EPI 
estimated glomerular filtration rate, antihypertensive therapy (based on 
participants’ self-reports list of drugs), blood Na+ and K+, and Na+ and 
K+ excretion. Models were further adjusted for study center to take into 
account the potential clustering of caffeine excretion and BP measure-
ments by center. Relationship between 24-hour, daytime, and night-time 
SBP with 24-hour urinary excretions of caffeine and paraxanthine in 
quartiles are presented. After verifying that the linearity of associa-
tion failed to be rejected, linear trends by urinary excretion of caffeine 
(respectively, paraxanthine) in quartiles (coded from 1 to 4) were tested 
using multilevel mixed-effects linear regression and P values reported 
(P for linear trend across quartiles). We also assessed the association of 
24-hour, daytime, and night-time urinary caffeine and metabolites sepa-
rately with the corresponding 24-hour, daytime, and night-time SBP 
and DBP. The actual awake and asleep periods were used, as reported 
by participants, to define daytime and night-time. BP and urine were, 
respectively, monitored and collected during 24-hour. Daytime col-
lection usually started between 6 am and 10 am and ended at reported 
bedtime. Night-time collection started at bedtime and ended after the 
first morning urine. Creatinine excretion per body weight (kg) and urine 
volume were entered as covariates in sensitivity analysis models to 
account for the quality of urine collections. Sensitivity analyses were 
conducted to explore the association of ABPM with urinary caffeine 
and its major metabolite, paraxanthine, by participants’ characteristics. 
For these sensitivity analyses, medians of continuous variables were 
used to categorize participants (except for body mass index and esti-
mated glomerular filtration rate for which the general cutoff of 25 kg/m2 
and 60 mL/min/1.73 m2 were used, respectively). Statistical interac-
tions between participants’characteristics and urinary caffeine excre-
tion were tested using Wald tests. Significant interaction product terms 
were then included in the adjusted models. Given the apparent increased 
association between caffeine urinary excretion and BP in adults with 
antihypertensive therapy in preliminary analysis, stratified analyses by 
antihypertensive therapy were performed. Statistical significances for 
association and interaction were set at P value <0.05. Only those indi-
viduals for whom all covariates of interest for the purpose of this study 
were available were included in the analysis. All analyses were con-
ducted using Stata, version 12.0 (StataCorp LP, College Station, TX).
Results
Among the 4173 eligible subjects invited to participate in the 
SKIPOGH study, 1128 (27.1%) participated and 836/1128 
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(74%) were included in the analysis. The main reason for par-
ticipants to be excluded from the analysis were missing data 
on night-time BP (N=233) or day time BP (N=166), no data 
on 24-hour Na+, K+, or caffeine urinary excretions (N=38). 
Participants not included differed from participants included 
by urinary methylxanthines excretions, urinary 24-hour 
sodium excretion, smoking status, and night-time BP. Among 
the participants included (Table 1), the overall mean (±SD) of 
age, 24-hour SBP, and DBP were 47.8 (±17.5), 120.1 (±13.9) 
mm Hg, and 78.0 (±8.6) mm Hg, respectively. Urinary excre-
tions of caffeine, paraxanthine, theophylline, and theobromine 
were highly skewed with medians of 3140.3, 10 177.5, 935.0, 
and 11 134.6 μg/24-hour, respectively. Night-time methylxan-
thines excretions were lower than daytime excretions. Fifteen 
percent were on antihypertensive therapy.
Figure presents, respectively, adjusted relationship of 24-hour, 
daytime, and night-time SBP with caffeine and, respectively, 
paraxanthine quartiles urinary excretions. Adjusted night-time 
SBP in the first (lowest), second, third, and fourth (highest) 
quartile of caffeine urinary excretions were 110.2 (0.9), 107.5 
(0.9), 106.0 (0.9), and 106.2 (0.9) mm Hg, respectively. Adjusted 
night-time SBP in the second, third, and fourth quartiles differed 
significantly from the first (reference) quartiles. Adjusted night-
time SBP in the first (lowest), second, third, and fourth (high-
est) quartile of paraxanthine urinary excretions were 110.3 (0.9), 
107.3 (0.9), 107.3 (0.9), and 105.1 (0.9) mm Hg, respectively. 
Adjusted night-time SBP in the second, third, and fourth quar-
tiles differed significantly from the first (reference) quartiles.
Table 2 displays the adjusted associations of 24-hour, day-
time, and night-time SBP and DBP with urinary caffeine and 
caffeine metabolite excretions, respectively. Log-transformed 
urinary caffeine excretions were associated inversely with 
24-hour and night-time ambulatory SBP. 24-hour and night-
time ambulatory SBP decreased by 0.642 (SE, 0.296) and 
1.107 (0.315) mm Hg (both P values <0.040) for each dou-
bling excretion of caffeine. Stronger inverse associations with 
night-time ambulatory SBP were observed for paraxanthine 
and theophylline. Night-time ambulatory SBP decreased by 
1.376 (SE, 0.364) and 1.183 (0.363) mm Hg (both P values 
<0.020) for each doubling excretion of paraxanthine and the-
ophylline, respectively. No associations of theobromine levels 
with 24-hour or night-time ambulatory SBP were observed.
No associations of 24-hour, daytime, or night-time diastolic 
BP with 24-hour urinary excretions of caffeine, paraxanthine, 
theophylline, or theobromine were generally found (Table 2).
Adjusted associations of 24-hour, daytime, and night-time 
SBP and DBP separately with daytime and night-time urinary 
caffeine and caffeine metabolite excretions are displayed in 
Table S1 in the online-only Data Supplement. These separate 
analyses showed that the associations of SBP with methylxan-
thines are generally driven by daytime methylxanthine excre-
tions. In addition, DBP—especially 24-hour and daytime 
DBP—appeared to be positively associated with night-time 
excretions of caffeine, paraxanthine, and theophylline.
Table S2 in the online-only Data Supplement displays the 
adjusted associations of 24-hour, daytime, and night-time SBP 
and DBP with 24-hour urinary caffeine and caffeine metabolite 
excretions by antihypertensive therapy status. Inverse associa-
tions were stronger among participants with antihypertensive 
therapy than participants without antihypertensive therapy. 
Twenty-four hour, daytime, and night-time ambulatory SBP 
decreased by >3 mm Hg (all P values <0.005) for each dou-
bling excretion of caffeine and caffeine metabolites (except 
theobromine). Inverse associations among participants without 
antihypertension therapy were found for night-time SBP.
Figures S1 in the online-only Data Supplement illustrates 
the adjusted associations of 24-hour, daytime, and night-time 
SBP with log-transformed urinary caffeine excretions for differ-
ent participants’ characteristics. The associations of SBP with 
urinary caffeine excretions were modified by antihypertensive 
Table 1. Participants’ Characteristics, SKIPOGH Study 
(N=836)
Charateristics All (N=836, 100%)
Male sex, % 409 (48.9)
Smokers, % 188 (22.5)
Contraceptive use, % among women 347 (81.3)
Current alcohol use, % 532 (63.6)
Diabetes mellitus, % 38 (4.5)
Anti-hypertensive treatment, % 132 (15.8)
Age, mean (SD) 47.8 (17.5)
BMI, kg/m2, mean (SD) 24.9 (4.3)
eGFR (CKD-EPI), mL/min/1.72 m2 (SD) 96.4 (17.8)
Serum Na+, mmol/L (SD) 140.4 (2.5)
Serum K+, mmol/L (SD) 4.1 (0.3)
24-hour Na+ urinary excretion (SD) 144.8 (62.7)
24-hour K+ urinary excretion (SD) 64.5 (22.9)
Urinary methylxanthine excretions
  24-hour
   Caffeine median (IQR), μg/24 h 3140.3 (3967.8)
   Paraxanthine median (IQR), μg/24 h 10 177.5 (10 966.8)
   Theophylline median (IQR), μg/24 h 935.0 (999.2)
   Theobromine median (IQR), μg/24 h 11 134.6 (12 498.3)
  Day time
   Caffeine median (IQR), μg/d 2250.0 (3004.645)
   Paraxanthine median (IQR), μg/d 6840.0 (7836.7)
   Theophylline median (IQR), μg/d 600.7 (722.3)
   Theobromine median (IQR), μg/d 6936.1 (8504.8)
  Night-time
   Caffeine median (IQR), μg/night 617.2 (1033.6)
   Paraxanthine median (IQR), μg/night 2925.9 (3598.1)
   Theophylline median (IQR), μg/night 288.5 (334.4)
   Theobromine median (IQR), μg/night 3273.2 (4414.9)
Ambulatory blood pressure (mm Hg)
  24-hour SBP (SD) 120.1 (13.9)
  Day SBP (SD) 124.0 (14.7)
  Night SBP (SD) 107.5 (14.4)
  24-hour DBP (SD) 78.0 (8.6)
  Day DBP (SD) 81.1 (9.6)
  Night DBP (SD) 68.1 (8.3)
BMI indicates body mass index; DBP, diastolic blood pressure; IQR, interquartile 
range; SBP, systolic blood pressure; SD, standard deviation; and SKIPOGH, Swiss 
Kidney Project on Genes in Hypertension.
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therapy, diabetes mellitus, and alcohol consumption. When these 
3 interaction terms were all included in the adjusted models, all 
3 interaction terms remained statistically significant with respect 
to night-time SBP (P values for interaction <0.05), whereas only 
antihypertensive and alcohol consumption modified the associa-
tion of caffeine with both 24-hour and daytime SBP.
Discussion
In this population-based sample, we found that urinary caf-
feine, paraxanthine, and theophylline excretions were, in gen-
eral, inversely associated with ambulatory SBP. To the best 
of our knowledge, no previous population-based study has 
looked at the association of measured urinary caffeine and caf-
feine metabolites on ambulatory BP. Our results are compat-
ible with a protective effect of caffeine on high BP and hence 
on arterial hypertension.
Each doubling of the excretion of caffeine was associated 
with a 0.6 mm Hg lower 24-hour ambulatory SBP. Studies 
have shown that caffeine induces diuresis and natriuresis, and 
animal models have shown that intact adenosine receptors are 
required for the natriuretic action of caffeine.19 Natriuresis 
associated with adenosine receptor blockade is thought to 
be caused by inhibition of proximal tubular reabsorption.19 
Further studies should ideally measure sodium proximal tubu-
lar reabsorption and determine its role in the caffeine–BP 
relation. Other methylxanthine-related mechanisms possibly 
involved include sympathomimetic effects, smooth muscle 
relaxation, and phosphodiesterase inhibition.20,21
We found no consistent association of 24-hour caffeine and 
caffeine metabolite excretions with DBP. Although the reason 
of the differential associations of caffeine and caffeine metab-
olites on SBP and DBP is not entirely clear, it is compatible 
with the hypothesis that methylxanthines influence BP via their 
natriuretic property. Previous studies with 24-hour urine collec-
tion reported that Na+ excretion predominantly affect SBP and 
generally not DBP.22,23 An experimental study that explored the 
effects of acute caffeine on BP found no effect on DBP.24 It is also 
possible that the adaptation of SBP and DBP to caffeine is dif-
ferent. DBP has been shown to adapt to repeated caffeine expo-
sure, whereas SBP seems to consistently change in response to 
caffeine.25,26 Interestingly, our additional analyses based on day-
time and night-time excretions separately revealed that DBP—
especially 24-hour and daytime DBP—was in fact positively 
associated with night-time excretions of caffeine, paraxanthine, 
and theophylline. Although the reasons of the observed differ-
ential associations between SBP and DBP, on the one hand, and 
between daytime and night-time methylxanthine excretions, on 
the other hand, remained speculative, it may explain, in part, the 
inconsistencies reported from previous studies that explored the 
association of caffeine with BP or hypertension. Inverse associa-
tions of 24-hour caffeine and caffeine metabolite excretions with 
SBP were strong during night-time. This could be explained, in 
part, by the fact that night-time BP is less influenced by envi-
ronmental factors than daytime (and therefore 24-hour) BP, a 
Table 2. Adjusted Associations of Systolic and Diastolic 
Ambulatory Blood Pressure With 24-Hour Urinary 
Methylxanthines Excretions
Systolic BP Diastolic BP
Methylxanthine Beta, SE P Value Beta, SE P Value
Caffeine*
  24 h −0.642, 0.296 0.030 0.252, 0.182 0.166
  Day −0.505, 0.313 0.107 0.342, 0.202 0.091
  Night −1.107, 0.315 <0.001 −0.074, 0.183 0.686
Paraxanthine*
  24 h −0.718, 0.343 0.036 0.353, 0.211 0.094
  Day −0.545, 0.362 0.132 0.442, 0.234 0.059
  Night −1.376, 0.364 <0.001 −0.039, 0.212 0.851
Theophylline*
  24 h −0.633, 0.341 0.064 0.391, 0.209 0.062
  Day −0.458, 0.360 0.204 0.530, 0.232 0.022
  Night −1.183, 0.363 0.001 −0.032, 0.211 0.881
Theobromine*
  24 h 0.302, 0.338 0.372 0.237, 0.208 0.254
  Day 0.325, 0.357 0.363 0.263, 0.230 0.254
  Night 0.003, 0.361 0.993 −0.015, 0.209 0.942
Models are adjusted for age, sex, BMI, study center, contraceptive 
use, diabetes mellitus, current alcohol use and smoking, GFR (CKD-EPI), 
antihypertensive treatment, blood Na+ and K+, and Na+ and K+ excretion. P 
values highlighted in bold are statistically significant (P<0.05). BMI indicates 
body mass index; BP, blood pressure; and GFR, glomerular filtration rate.
*Log-transformed.
Figure. Adjusted associations (standard 
error) of 24-hour, daytime, night-time 
systolic blood pressure with quartiles of 
24-hour urinary caffeine and paraxanthine 
excretions (N=836). adjusted for age, 
sex, body mass index, study center, 
contraceptive use, diabetes mellitus, current 
alcohol use, smoking, glomerular filtration 
rate (CKD-EPI), blood Na+ and K+, and Na+ 
and K+ excretion.
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phenomenon previously reported in studies investigating the 
genetics of hypertension.27 It is also possible that the inverse 
association during daytime is blunted by an acute pressure effect 
of caffeine intake during the morning. The stronger associations 
of night-time BP than daytime BP with caffeine is of impor-
tance, given the increasing evidence that night-time BP provides 
the greatest information regarding cariovascular risk.28
Similar results were observed for paraxanthine and theoph-
ylline. In fact, among all caffeine and caffeine metabolites, 
strong inverse association of paraxanthine with SBP was found. 
This is in line with the fact that paraxanthine is slightly more 
potent than caffeine in antagonising the effects of adenosine.29
Although theobromine has also been shown to increase 
natriuresis and to present similar properties than other meth-
ylxanthines,21 we found no significant association of theobro-
mine with BP. Theobromine has one fifth the stimulant effect 
of caffeine, and acute theobromine and caffeine intake have 
previously been shown to exert opposite results on BP among 
24 healthy female volunteers.30
Interaction analysis suggested that antihypertensive ther-
apy, diabetes mellitus, and alcohol consumption modify the 
association of caffeine urinary excretion with ambulatory 
SBP. It is possible that the potential diuretic effect of meth-
ylxanthines provides a synergistic effect to antihypertensive 
drugs. Of note, among participants with antihypertensive ther-
apy, daytime SBP was also inversely associated with caffeine 
urinary excretions. Previous systematic reviews and meta-
analysis on the effect of caffeinated beverages on BP have not 
stratified their analysis by diabetes mellitus status, and we are 
not aware of previous studies showing a differential associa-
tion of caffeine with BP among individuals with and without 
type 2 diabetes mellitus.31 The particularly strong associations 
in patients with antihypertensive therapy or diabetes mellitus 
deserve to be further explored. The stronger inverse associa-
tion observed in participants who reported no alcohol con-
sumption than participants who reported alcohol consumption 
is in line with previous evidence showing that long-term etha-
nol consumption masks the induction of CYP1A2 activity.32 
The significant interactions further suggest that the associa-
tion of caffeine with BP is modified by multiple factors.
All together, our results are compatible with a protective effect 
of caffeine on BP. Although of major interest, definitive answer 
on the relation of BP with caffeine is currently lacking.10 Also, 
cumulative evidence from clinical trials suggests that the acute 
and chronic effects of caffeine intake on BP may actually differ.33
Limitations and Strengths
The validity of caffeine and caffeine metabolites urinary excre-
tion measurements depends on the quality of urine collection. 
The mean urinary volume corrected for 24 hour, and creatinine 
excretion corrected for body weight of the participants included 
in the analysis suggested that the quality of urine collection 
was satisfactory. Further adjustment for 24-hour urine volume 
and creatinine excretion did not change the associations (data 
not shown). Previous studies suggested that associations of 
caffeinated beverages (ie, coffee intake) with cardiovascular 
outcomes (ie, myocardial infarction) or risk factors (ie, hyper-
tension) were modified by CYP1A2 genotype.9,34,35 Genetic 
information was not available in the present analysis. Although 
we considered major factors, the biological half-life of caf-
feine is highly variable among individuals (2–10 hours)36 and 
is influenced by several genetic and nongenetic determinants 
(eg, liver function) that we could not account for.
The cross-sectional nature of our study limits causal infer-
ence. Similarly, we cannot exclude reverse causality. Yet, 
participants with antihypertensive therapy tended to have a 
greater urinary caffeine excretion than participants without 
antihypertensive therapy (3530.5 versus 3002.4 μg/24 h; P 
value 0.058). Finally, we performed multiple comparisons, 
and concern about false-positive associations could be raised. 
Many comparisons were, however, correlated or subgroup 
analysis (and thus need not be corrected) and all night-time 
BP-related associations would remain significant using a con-
servative approach, such as the Bonferroni correction.37
Strengths of our study include its population-based nature, 
the large sample size, the availability of ABPM, and the use of 
a standardized protocol across 3 study centers. Studies have 
shown that ambulatory BP is superior to office BP in predicting 
future cardiovascular events and target organ damage.38 A large 
number of compounds other than caffeine are present in coffee, 
which limits the interpretation of many previous studies that 
assessed the role of caffeine on BP based on self-reported cof-
fee intake. In addition, the caffeine content of coffee is highly 
variable.39 To better disentangle the role of caffeine per se on 
BP, we directly measured caffeine and its main metabolites.
Perspectives
Ambulatory SBP was inversely associated with urinary caf-
feine and caffeine metabolites, paraxanthine and theophylline, 
in adults from the general population. Given the ubiquitous 
nature of caffeinated beverages and foods in the population, 
our results may have important public health effect.
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What Is New?
•	No previous study has ever addressed in a population-based study wheth-
er caffeine urinary excretion is associated with ambulatory blood pressure.
What Is Relevant?
•	 In our study, ambulatory systolic blood pressure was inversely associ-
ated with urinary excretions of caffeine and other caffeine metabolites.
Summary
Results from this population-based study with 24-hour caffeine uri-
nary excretion and ambulatory blood pressure are compatible with 
a protective effect of caffeine on blood pressure.
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Table S1. Adjusted associations of systolic and diastolic ambulatory blood pressure with day and night‐time urinary 
methylxanthines excretions  
  Daytime urinary methylxanthines excretions Night‐time urinary methylxanthines excretions
  Systolic  Diastolic Systolic  Diastolic
Methylxanthine    Beta,  
SE 
P  
value 
Beta, 
SE 
P 
value 
Beta, 
SE 
P 
value 
Beta, 
SE 
P 
value 
Caffeine*  SBP 24h  ‐0.718, 0.280  0.010 DBP 24h 0.172, 0.172 0.319 SBP 24h  0.028, 0.252 0.911 DBP 24h 0.373, 0.154 0.016 
  SBP day  ‐0.547, 0.313  0.065 DBP day 0.281, 0.191 0.142 SBP day  0.063, 0.266 0.814 DBP day 0.408, 0.171 0.017 
  SBP night  ‐1.323, 0.315  <0.001 DBP night ‐0.246, 0.173 0.155 SBP night  ‐0.048, 0.269 0.858 DBP night 0.308, 0.155 0.048 
Paraxanthine*  SBP 24h  ‐0.748, 0.320  0.019 DBP 24h 0.318, 0.197 0.106 SBP 24h  ‐0.235, 0.304 0.439 DBP 24h 0.360, 0.186 0.053 
  SBP day  ‐0.568, 0.338  0.093 DBP day 0.414, 0.218 0.058 SBP day  ‐0.125, 0.321 0.696 DBP day 0.415, 0.207 0.044 
  SBP night  ‐1.509, 0.339  <0.001 DBP night ‐0.159, 0.198 0.422 SBP night  ‐0.505, 0.324 0.119 DBP night 0.242, 0.187 0.196 
Theophylline*  SBP 24h  ‐0.706, 0.321  0.028 DBP 24h 0.341, 0.198 0.085 SBP 24h  ‐0.268, 0.314 0.393 DBP 24h 0.381, 0.192 0.048 
  SBP day  ‐0.521, 0.340  0.125 DBP day 0.485, 0.219 0.027 SBP day  ‐0.141, 0.331 0.671 DBP day 0.482, 0.213 0.024 
  SBP night  ‐1.378, 0.341  <0.001 DBP night ‐0.169, 0.199 0.394 SBP night  ‐0.523, 0.334 0.118 DBP night 0.199, 0.194 0.304 
Theobromine*  SBP 24h  0.121, 0.325  0.710 DBP 24h 0.212, 0.200 0.287 SBP 24h  ‐0.389, 0.289 0.179 DBP 24h 0.166, 0.178 0.350 
  SBP day  0.144, 0.343  0.675 DBP day 0.237, 0.221 0.284 SBP day  ‐0.383, 0.305 0.209 DBP day 0.177, 0.197 0.369 
  SBP 
night 
‐0.237, 
0.347 
0.495  DBP 
night 
‐0.084, 
0.201 
0.67
4 
SBP 
night 
0.342, 0.309  0.26
8 
DBP 
night 
0.113, 
0.179 
0.527 
Models  are adjusted for age, sex, BMI, study center, contraceptive use, diabetes, current alcohol use and smoking, GFR (CKD‐EPI), 
anti‐hypertensive treatment, blood Na+ and K+, and Na+ and K+ excretion. *log‐transformed 
  
Table S2. Adjusted associations of systolic (SBP) and diastolic (DBP) blood pressure with 24‐hour urinary methylanthines 
excretions  
  NOT on anti‐hypertensive therapy (N=704, 84.2%) On anti‐hypertensive therapy (N=132, 15.8%)
  Systolic  Diastolic Systolic  Diastolic
Methylxanthine    Beta,  
SE 
P  
value 
Beta, 
SE 
P 
value 
Beta, 
SE 
P 
value 
Beta, 
SE 
P 
value 
Caffeine*  SBP 24h  ‐0.451, 0.311  0.147 DBP 24h 0.212, 0.186 0.255 SBP 24h  ‐3.192, 0.960 0.001 DBP 24h ‐0.408, 0.626 0.515 
  SBP day  ‐0.312, 0.330  0.344 DBP day 0.280, 0.206 0.174 SBP day  ‐3.088, 0.994 0.002 DBP day ‐0.186, 0.707 0.793 
  SBP night  ‐0.901, 0.325  0.006 DBP night ‐0.064, 0.194 0.741 SBP night  ‐3.616, 1.091 0.001 DBP night ‐1.093, 0.542 0.044 
Paraxanthine*  SBP 24h  ‐0.533, 0.361  0.140 DBP 24h 0.314, 0.216 0.145 SBP 24h  ‐3.235, 1.090 0.003 DBP 24h ‐0.448, 0.706 0.526 
  SBP day  ‐0.347, 0.382  0.365 DBP day 0.414, 0.239 0.083 SBP day  ‐3.186, 1.127 0.005 DBP day ‐0.501, 0.796 0.529 
  SBP night  ‐1.209, 0.377  0.001 DBP night ‐0.092, 0.224 0.681 SBP night  ‐3.558, 1.242 0.004 DBP night ‐0.565, 0.617 0.360 
Theophylline*  SBP 24h  ‐0.374, 0.362  0.303 DBP 24h 0.338, 0.216 0.119 SBP 24h  ‐3.481, 1.020 0.001 DBP 24h ‐0.342, 0.667 0.608 
  SBP day  ‐0.186, 0.384  0.628 DBP day 0.476, 0.239 0.047 SBP day  ‐3.415, 1.056 0.001 DBP day ‐0.228,  0.753 0.762 
  SBP night  ‐0.928, 0.379  0.014 DBP night ‐0.069, 0.225 0.759 SBP night  ‐3.798, 1.163 0.001 DBP night ‐0.839, 0.581 0.149 
Theobromine*  SBP 24h  0.474, 0.359  0.187 DBP 24h 0.261, 0.214 0.224 SBP 24h  ‐1.021, 1.024 0.319 DBP 24h 0.320, 0.644 0.619 
  SBP day  0.497, 0.380  0.191 DBP day 0.297, 0.238 0.211 SBP day  ‐0.995, 1.056 0.346 DBP day ‐0.334, 0.726 0.646 
  SBP night  0.215, 0.377  0.568 DBP night 0.014, 0.223 0.949 SBP night  ‐1.527, 1.160 0.188 DBP night ‐0.656, 0.562 0.244 
 
Models  are adjusted for age, sex, BMI, study center, contraceptive use, diabetes, current alcohol use and smoking, GFR (CKD‐EPI), 
blood Na+ and K+, and Na+ and K+ excretion. *log‐transformed 
Figure S1. 
 
Figure S1 Adjusted associations of 24‐hour, daytime, and night‐time systolic blood pressure with log 
transformed urinary 24‐hour caffeine excretions, by participants’ characteristics (N=836) 
Footnote: adjusted for age, sex, BMI, study center, contraceptive use, diabetes, current alcohol use, smoking, GFR 
(CKD‐EPI), blood Na+ and K+, and Na+ and K+ excretion. 
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